Latest Research And Development News

Page 4 of 115
Merino & Co. entered FY2027 with A$1.404 million in cash after a A$1.010 million capital raising, giving the company more room to develop its botanical dye project and expand fulfilment. The stronger balance sheet came alongside a A$164,000 operating cash outflow and fully drawn NAB loan facilities.
Victor Sage
Victor Sage
30 Oct 2026
PARKD has secured two early-stage contracts, added Symal as its exclusive partner in Victoria and South Australia, and lifted pro forma cash to about A$850,000 through a strategic placement. The progress comes against a sharp liquidity squeeze, with just A$53,000 in cash at 30 September and funding equivalent to 0.21 quarters before the raise.
Victor Sage
Victor Sage
30 Oct 2026
Syntara has reported statistically significant exploratory results for its Parkinson’s-related drug SNT-4728, while advancing blood-cancer and scar studies. The quarter also brought A$4.7 million in R&D funding, but the liquidation of a former buyer threatens a facility relocation and recovery of about A$0.6 million.
Ada Torres
Ada Torres
30 Oct 2026
Zelira Therapeutics has only A$47,000 in cash after a quarterly operating outflow of A$56,000, while the proposed US$32.98 million HOPE 1 fundraising remains unclosed. The company says the funds are needed for an FDA application and Phase 1 trial, as its ASX quotation suspension continues.
Victor Sage
Victor Sage
30 Oct 2026
Invex Therapeutics has paired its proposed acquisition of Rekover Therapeutics with a $10 million equity raising to fund a Phase 2a multiple sclerosis study and its existing Exenatide programs. The biotech ended September with A$3.59 million in cash, with shareholder approval still required for the larger part of the transaction.
Ada Torres
Ada Torres
30 Oct 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
Victor Sage
30 Oct 2026
Cann Group’s September quarter delivered a sharp increase in revenue and exports as its Mildura GMP facility gained traction in Europe. But with just $49,000 in cash, $626,000 of undrawn debt capacity and an estimated 0.9 quarters of funding, the recovery still depends on collections and further financing.
Ada Torres
Ada Torres
30 Oct 2026
Dotz Nano has secured commitments for a A$2 million placement while proposing to acquire PRF Technologies’ GridFeed software for US$1 million paid over 21 months. The move would broaden its energy strategy from building-level cooling optimisation into renewable generation, storage and grid analytics, but the deal and much of the commercial pipeline remain conditional.
Victor Sage
Victor Sage
30 Oct 2026
Legacy Minerals has lifted its Mt Carrington resource by 39% to 47.9 million tonnes, giving it scope to test a larger processing operation. The opportunity arrives alongside a tighter funding picture, with $3.5 million in cash and estimated funding of 1.75 quarters at current outgoings.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive